Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call.

Tony J. Hunt, President and Chief Executive Officer said, “I’m pleased to report that the company delivered outstanding financial performance during the second quarter as we continue to focus on keeping all our manufacturing sites fully operational and managing our supply chain and logistics while also prioritizing the health and safety of our employees. During the second quarter, we saw increased demand in all of our product franchises, highlighted by strong growth in Asia and a significant pick up in orders both in the quarter and into the second half of 2020 related to COVID-19 vaccine and therapeutic programs. We finished the quarter by announcing our acquisition of Engineered Molding Technology, which closed in July, to enhance our single-use portfolio. We are confident about the full year outlook for the company and are updating guidance to reflect our expectations for margin expansion and revenue growth in the range of 23%-26%.”.

Financial Highlights for the Second Quarter 2020

  • Revenue increased by 24% year-over-year as reported and 19% organically, to $87.5 million
  • GAAP gross margin increased to 57.9%, and adjusted gross margin (non-GAAP) was 58.2%
  • GAAP fully diluted EPS increased to $0.30 compared to $0.17 for the second quarter of 2019
  • Adjusted fully diluted EPS (non-GAAP) increased to $0.42 compared to $0.33 for the second quarter of 2019

Financial Highlights for the First Half of 2020

  • Revenue increased by 25% year-over-year as reported and 17% organically, to $163.6 million
  • GAAP gross margin increased to 57.9%, and adjusted gross margin (non-GAAP) was 58.3%
  • GAAP fully diluted EPS increased to $0.48 compared to $0.34 for the first half of 2019
  • Adjusted fully diluted EPS (non-GAAP) increased to $0.74 compared to $0.59 for the first half of 2019

Financial Details for the Second Quarter and First Half of 2020REVENUE

  • Total revenue for the second quarter of 2020 increased to $87.5 million compared to $70.7 million for the second quarter of 2019, a year-over-year gain of 24% as reported and 25% at constant currency, with organic growth of 19%.
  • Total revenue for the first half of 2020 increased to $163.6 million compared to $131.3 million for the first half of 2019, a year-over-year gain of 25% as reported.

GROSS PROFIT and GROSS MARGIN

  • Gross profit (GAAP) for the second quarter of 2020 was $50.6 million, a year-over-year increase of $10.6 million and representing 57.9% gross margin.
  • Adjusted gross profit (non-GAAP) for the second quarter of 2020 was $50.9 million, a year-over-year increase of $9.5 million and representing 58.2% gross margin.
  • Gross profit (GAAP) for the first half of 2020 was $94.7 million, a year-over-year increase of $20.9 million and representing 57.9% gross margin.
  • Adjusted gross profit (non-GAAP) for the first half of 2020 was $95.4 million, a year-over-year increase of $20.1 million and representing 58.3% gross margin. 

OPERATING INCOME

  • Operating income (GAAP) for the second quarter of 2020 was $19.5 million compared to $11.1 million for the second quarter of 2019. Adjusted operating income (non-GAAP) for the second quarter of 2020 was $25.5 million, an increase of 27% compared to $20.1 million for the second quarter of 2019.
  • Operating income (GAAP) for the first half of 2020 was $31.4 million compared to $22.2 million for the first half of 2019. Adjusted operating income (non-GAAP) for the first half of 2020 was $43.9 million, an increase of 23% compared to $35.7 million for the first half of 2019.

NET INCOME

  • Net income (GAAP) for the second quarter of 2020 was $15.9 million, an increase of 96% compared to $8.1 million for the second quarter of 2019. Adjusted net income (non-GAAP) for the second quarter of 2020 was $22.5 million, an increase of 39% compared to $16.2 million for the second quarter of 2019.
  • Net income (GAAP) for the first half of 2020 was $25.7 million, an increase of 59% compared to $16.1 million for the first half of 2019. Adjusted net income (non-GAAP) for the first half of 2020 was $39.3 million, an increase of 38% compared to $28.4 million for the first half of 2019.

EARNINGS PER SHARE

  • Earnings per share (GAAP) for the second quarter of 2020 increased to $0.30 on a fully diluted basis, compared to $0.17 for the second quarter of 2019. Adjusted EPS (non-GAAP) for the second quarter of 2020 increased to $0.42 on a fully diluted basis, compared to $0.33 for the 2019 period.
  • Earnings per share (GAAP) for the first half of 2020 increased to $0.48 on a fully diluted basis, compared to $0.34 for the first half of 2019. Adjusted EPS (non-GAAP) for the first half of 2020 increased to $0.74 on a fully diluted basis, compared to $0.59 for the first half of 2019.

EBITDA

  • EBITDA, a non-GAAP financial measure, increased to $25.3 million for the second quarter of 2020, compared to $15.2 million for the second quarter of 2019. Adjusted EBITDA for the second quarter of 2020 increased to $27.4 million, compared to $21.7 million for the second quarter of 2019.
  • EBITDA increased to $43.9 million for the first half of 2020, compared to $30.9 million for the first half of 2019. Adjusted EBITDA for the first half of 2020 increased to $48.6 million, compared to $39.2 million for the first half of 2019.

CASH

  • Our cash and cash equivalents at June 30, 2020 were $560.4 million, an increase of $32 million from $528.4 million at December 31, 2019.

All reconciliations of GAAP to adjusted (non-GAAP) figures above, as well as EBITDA to adjusted EBITDA, are detailed in the reconciliation tables included later in this press release.

Financial Guidance for 2020

Our financial guidance for the fiscal year 2020 is based on expectations for our existing business and includes the financial impact of our acquisition of C Technologies (which closed on May 31, 2019) and Engineered Molding Technology (which closed on July 13, 2020). The guidance below excludes the impact of potential additional acquisitions and future fluctuations in foreign currency exchange rates. 

FISCAL YEAR 2020 GUIDANCE:

  • Total revenue is projected to be in the range of $332-$340 million, an increase from our previous guidance of $309-$319 million. Our current guidance reflects overall revenue growth of 23%-26%, and organic revenue growth of 18%-21%.  
  • Gross margin is expected to be in the range of 56.5%-57.0% on both a GAAP and non-GAAP basis, compared to our previous guidance of 56%-57%. 
  • Income from operations is expected to be in the range of $59-$62 million on a GAAP basis, an increase from our previous guidance of $52-$56 million. Adjusted (non-GAAP) income from operations is expected to be in the range of $81-$84 million, an increase from our previous guidance of $72-$76 million.  
  • Net income is expected to be in the range of $41-$44 million on a GAAP basis, an increase from our previous guidance of $34.5-$37.5 million. Adjusted (non-GAAP) net income is expected to be in the range of $66-$69 million, an increase from our previous guidance of $58-$61 million. Our current guidance reflects an adjusted tax rate of 18% on adjusted pre-tax income, compared to our previous guidance of 20%.
  • Fully diluted GAAP EPS is expected to be in the range of $0.77-$0.82, an increase from our previous guidance of $0.65-$0.70. Adjusted (non-GAAP) fully diluted EPS is expected to be in the range of $1.24-$1.29, an increase from our previous guidance of $1.09-$1.14.

 Our non-GAAP guidance for the fiscal year 2020 excludes the following items:

  • $5.7 million estimated acquisition and integration expenses; $0.5 million in cost of product revenue, $0.5 million in R&D and $4.7 million in SG&A.
  • Expected inventory step-up charges of $0.2 million related to the acquisition of Engineered Molding Technology.
  • $15.7 million estimated intangible amortization expense; $0.3 million in cost of product revenue and $15.5 million in SG&A.
  • $11.0 million of non-cash interest expense (Other income (expense)) related to our convertible debt notes.

Our non-GAAP guidance for the fiscal year 2020 includes:

  • An income tax expense of $7.8 million, representing the tax impact of acquisition and integration, inventory step-up, and intangible amortization expenses, as well as non-cash interest expenses related to our convertible debt notes.

All reconciliations of GAAP to adjusted (non-GAAP) guidance are detailed in the tables included later in this press release.

Conference CallRepligen will host a conference call and webcast today, July 30, 2020, at 8:30 a.m. EDT, to discuss second quarter 2020 financial results and corporate developments. The conference call will be accessible by dialing toll-free (844) 701-1063 for domestic callers or (412) 317-5487 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 10146361.

Non-GAAP Measures of Financial Performance To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: revenue growth rate at constant currency, adjusted gross profit and adjusted gross margin, adjusted income from operations and adjusted operating margin, earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted EBITDA, adjusted net income, adjusted net income per share, adjusted earnings per diluted share (EPS), adjusted cost of sales, adjusted research & development expense, adjusted selling, general and administrative expense, adjusted income tax expense and adjusted income tax rate. The Company provides organic revenue growth rates in constant currency to exclude the impact of both foreign currency translation, and the impact of acquisition revenue for current year periods that have no prior year comparable, in order to facilitate a comparison of its current revenue performance to its past revenue performance. The Company provides revenue growth rates in constant currency in order to facilitate a comparison of its current revenue performance to its past revenue performance. To calculate revenue growth rates in constant currency, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period.

The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition and integration costs, inventory step-up charges and intangible amortization costs related to the Company’s acquisitions, as well as non-cash interest expenses related to the Company’s convertible debt, and the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company’s operating performance and guidance investors should not consider non-GAAP measures as substitutable for the comparable financial measures prepared in accordance with GAAP.

About Repligen CorporationRepligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, MA (USA), and we have additional administrative and manufacturing operations in Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Clifton Park, NY; Lund, Sweden; Breda, The Netherlands and Ravensburg, Germany.

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, including cash and investment position, demand in the markets in which we operate, the expected performance of our business, the expected performance of the C Technologies and Engineered Molding Technology businesses, the expected performance and success of our strategic partnerships, management’s strategy, plans and objectives for future operations or acquisitions, product development and sales, selling, general and administrative expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources, our financing plans, and the projected impact of, and response to, the COVID-19 coronavirus pandemic, and the related downturn of the U.S. and global economies constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with the following: the effect of the COVID-19 coronavirus pandemic, including mitigation efforts and economic effects, on our business operations and the operations of our customers and suppliers; the ultimate impact of the COVID-19 coronavirus pandemic on our business or financial results; our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities; our ability to successfully integrate any acquisitions, our ability to develop and commercialize products and the market acceptance of our products; our ability to integrate the C Technologies and Engineered Molding Technology businesses successfully into our business and achieve the expected benefits of the acquisitions; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all U.S. Food and Drug Administration and EMEA regulations; our volatile stock price; and other risks detailed in Repligen’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward-looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law. 

Repligen Contact:  Sondra S. NewmanGlobal Head of Investor Relations(781) 419-1881investors@repligen.com

REPLIGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except share and per share data)
           
  Three Months Ended June 30,   Six Months Ended June 30,
    2020       2019       2020       2019  
               
Revenue:              
Product revenue $ 87,432     $ 70,670     $ 163,492     $ 131,282  
Royalty and other revenue   30       22       60       44  
Total revenue   87,462       70,692       163,552       131,326  
Costs and expenses:              
Cost of product revenue   36,863       30,708       68,845       57,553  
Research and development   4,336       5,231       9,038       8,851  
Selling, general and administrative   26,726       23,699       54,226       42,697  
    67,925       59,638       132,109       109,101  
Income from operations   19,537       11,054       31,443       22,225  
Investment income   253       1,005       1,617       1,718  
Interest expense   (3,004 )     (1,743 )     (5,980 )     (3,469 )
Other income, net   (766 )     (697 )     (384 )     (339 )
Income before income taxes   16,020       9,619       26,696       20,135  
Income tax provision   159       1,524       1,020       3,987  
Net income $ 15,861     $ 8,095     $ 25,676     $ 16,148  
Earnings per share:              
Basic $ 0.30     $ 0.17     $ 0.49     $ 0.36  
Diluted $ 0.30     $ 0.17     $ 0.48     $ 0.34  
Weighted average shares outstanding:              
Basic   52,381,201       46,367,187       52,259,937       45,174,134  
Diluted   53,305,827       49,055,814       53,212,596       47,691,772  
               
               
               
Balance Sheet Data: June 30, 2020   December 31, 2019        
Cash, cash equivalents and marketable securities $ 560,364     $ 528,392          
Working capital   642,756       593,515          
Total assets   1,442,045       1,400,113          
Long-term obligations   297,617       292,032          
Accumulated earnings   31,519       5,843          
Stockholders' equity   1,100,027       1,059,768          
REPLIGEN CORPORATION
RECONCILIATION OF GAAP INCOME FROM OPERATIONS TO NON-GAAP (ADJUSTED) INCOME FROM OPERATIONS
(Unaudited, amounts in thousands)
                 
    Three Months Ended June 30,   Six Months Ended June 30,
      2020       2019       2020       2019  
                 
GAAP INCOME FROM OPERATIONS $ 19,537     $ 11,054     $ 31,443     $ 22,225  
                 
ADJUSTMENTS TO INCOME (LOSS) FROM OPERATIONS:              
  Acquisition and integration costs   2,134       4,822       4,687       6,621  
  Intangible amortization   3,874       3,051       7,752       5,662  
  Inventory step-up charges   -       1,169       -       1,169  
                 
                 
ADJUSTED INCOME FROM OPERATIONS $ 25,545     $ 20,096     $ 43,882     $ 35,677  
                 
                 
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED) NET INCOME
(Unaudited, amounts in thousands)
                 
    Three Months Ended June 30,   Six Months Ended June 30,
      2020       2019       2020       2019  
                 
GAAP NET INCOME $ 15,861     $ 8,095     $ 25,676     $ 16,148  
                 
ADJUSTMENTS TO NET INCOME:              
  Acquisition and integration costs   2,134       5,322       4,687       7,121  
  Inventory step-up charges   -       1,169       -       1,169  
  Intangible amortization   3,874       3,051       7,752       5,662  
  Non-cash interest expense   2,724       1,124       5,415       2,231  
  Tax effect of non-GAAP charges (1)   (2,085 )     (2,610 )     (4,262 )     (3,961 )
                 
                 
ADJUSTED NET INCOME $ 22,508     $ 16,151     $ 39,268     $ 28,370  
                 
(1)   Effective as of the quarter ended June 30, 2019, the Company changed its methodology for calculating its non-GAAP financial measures to reflect certain tax effects related to acquisition and integration costs, intangible amortization and non-cash interest expense. Accordingly, the non-GAAP financial measures for the three months ended June 30, 2019 have been updated to be consistent with the methodology used to calculate such measures for the current period.
   
                 
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME PER SHARE TO NON-GAAP (ADJUSTED) NET INCOME PER SHARE
(Unaudited)
                 
    Three Months Ended June 30,   Six Months Ended June 30,
      2020       2019       2020       2019  
                 
GAAP NET INCOME PER SHARE - DILUTED $ 0.30     $ 0.17     $ 0.48     $ 0.34  
                 
ADJUSTMENTS TO NET INCOME PER SHARE - DILUTED:              
  Acquisition and integration costs   0.04       0.11       0.09       0.15  
  Inventory step-up charges   -       0.02       -       0.02  
  Intangible amortization   0.07       0.06       0.15       0.12  
  Non-cash interest expense   0.05       0.02       0.10       0.05  
  Tax effect of non-GAAP charges(1)   (0.04 )     (0.05 )     (0.08 )     (0.09 )
                 
                 
ADJUSTED NET INCOME PER SHARE - DILUTED   0.42     $ 0.33     $ 0.74     $ 0.59  
                 
Totals may not add due to rounding.              
                 
(1)   Effective as of the quarter ended June 30, 2019, the Company changed its methodology for calculating its non-GAAP financial measures to reflect certain tax effects related to acquisition and integration costs, intangible amortization and non-cash interest expense. Accordingly, the non-GAAP financial measures for the three months ended June 30, 2019 have been updated to be consistent with the methodology used to calculate such measures for the current period.
                 
                 
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA
(Unaudited, amounts in thousands)
                 
    Three Months Ended June 30,   Six Months Ended June 30,
      2020       2019       2020       2019  
                 
GAAP NET INCOME $ 15,861     $ 8,095     $ 25,676     $ 16,148  
                 
ADJUSTMENTS:              
  Investment Income   (253 )     (1,005 )     (1,617 )     (1,718 )
  Interest Expense   3,004       1,743       5,980       3,469  
  Tax Provision   159       1,524       1,020       3,987  
  Depreciation   2,578       1,762       5,063       3,337  
  Amortization(1)   3,902       3,079       7,807       5,716  
                 
EBITDA   25,251       15,198       43,929       30,939  
                 
OTHER ADJUSTMENTS:              
  Acquisition and integration costs   2,134       5,322       4,687       7,121  
  Inventory step-up charges   -       1,169       -       1,169  
                 
                 
ADJUSTED EBITDA $ 27,385     $ 21,689     $ 48,616     $ 39,229  
                 
(1 ) Includes amortization of milestone payments in accordance with GAAP of $27 for the three months ended June 30, 2020 and 2019 and $55 for the six months ended June 30, 2020 and 2019.
                 
                 
REPLIGEN CORPORATION
RECONCILIATION OF GAAP COST OF SALES TO NON-GAAP (ADJUSTED) COST OF SALES
(Unaudited, amounts in thousands)
                 
    Three Months Ended June 30,   Six Months Ended June 30,
      2020       2019       2020       2019  
                 
GAAP COST OF SALES $ 36,863     $ 30,708     $ 68,845     $ 57,553  
                 
ADJUSTMENT TO COST OF SALES:              
  Acquisition and integration costs   (185 )     (133 )     (465 )     (151 )
  Inventory step-up charges   -       (1,169 )     -       (1,169 )
  Intangible amortization   (127 )     (130 )     (254 )     (264 )
                 
                 
ADJUSTED COST OF SALES $ 36,551     $ 29,276     $ 68,126     $ 55,969  
                 
                 
REPLIGEN CORPORATION
RECONCILIATION OF GAAP R&D EXPENSE TO NON-GAAP (ADJUSTED) R&D EXPENSE
(Unaudited, amounts in thousands)
                 
    Three Months Ended June 30,   Six Months Ended June 30,
      2020       2019       2020       2019  
                 
GAAP R&D $ 4,336     $ 5,231     $ 9,038     $ 8,851  
                 
ADJUSTMENT TO R&D:              
  Acquisition and integration costs   (189 )     (100 )     (471 )     (127 )
                 
                 
ADJUSTED R&D $ 4,147     $ 5,131     $ 8,567     $ 8,724  
                 
                 
REPLIGEN CORPORATION
RECONCILIATION OF GAAP SG&A EXPENSE TO NON-GAAP (ADJUSTED) SG&A EXPENSE
(Unaudited, amounts in thousands)
                 
    Three Months Ended June 30,   Six Months Ended June 30,
      2020       2019       2020       2019  
                 
GAAP SG&A EXPENSE $ 26,726     $ 23,699     $ 54,226     $ 42,697  
                 
ADJUSTMENTS TO SG&A EXPENSE:              
  Acquisition and integration costs   (1,760 )     (4,590 )     (3,750 )     (6,343 )
  Intangible amortization   (3,747 )     (2,921 )     (7,498 )     (5,398 )
                 
                 
ADJUSTED SG&A EXPENSE $ 21,219     $ 16,188     $ 42,977     $ 30,956  
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME GUIDANCE TO ADJUSTED (NON-GAAP NET INCOME GUIDANCE)
         
(in thousands) Twelve months ending December 31, 2020
    Low End   High End
GUIDANCE ON NET INCOME $ 41,000     $ 44,000  
ADJUSTMENTS TO GUIDANCE ON NET INCOME:      
  Acquisition and integration costs   5,706       5,706  
  Anticipated pre-tax amortization of acquisition-related intangible assets   15,733       15,733  
  Inventory step-up costs   233       233  
  Non-cash interest expense   10,963       10,963  
  Tax effect of non-GAAP charges   (7,790 )     (7,790 )
  Guidance rounding adjustment   155       155  
GUIDANCE ON ADJUSTED NET INCOME $ 66,000     $ 69,000  
         
         
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME PER SHARE GUIDANCE TO
ADJUSTED (NON-GAAP) NET INCOME PER SHARE GUIDANCE
         
    Twelve months ending December 31, 2020
    Low End   High End
GUIDANCE ON NET INCOME PER SHARE - DILUTED $0.77     $0.82  
ADJUSTMENTS TO GUIDANCE ON NET INCOME PER SHARE - DILUTED:    
  Acquisition and integration costs $0.11     $0.11  
  Anticipated pre-tax amortization of acquisition-related intangible assets $0.29     $0.29  
  Inventory step-up costs $0.00     $0.00  
  Non-cash interest expense $0.21     $0.21  
  Tax effect of non-GAAP charges   ($0.15 )     ($0.15 )
  Guidance rounding adjustment $0.00     $0.00  
GUIDANCE ON ADJUSTED NET INCOME PER SHARE - DILUTED $1.24     $1.29  
         
Totals may not add due to rounding.      
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Repligen Charts.
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Repligen Charts.